Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

307
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
307
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

88
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
88
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

323
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
323
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.3K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

50
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
50

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.

The New England journal of medicine·2016
Same author

Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia.

Malaria journal·2016
Same author

The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.

FEMS microbiology reviews·2016
Same author

Reply to Meshnick and Hastings et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2016
Same author

Management of relapsing Plasmodium vivax malaria.

Expert review of anti-infective therapy·2016
Same author

Antimalarial mass drug administration: ethical considerations.

International health·2016
Same journal

Cefiderocol heteroresistance in NDM Enterobacterales.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 37-59.

The Lancet. Infectious diseases·2026
Same journal

Correction to Lancet Infect Dis 2020; 20: 60-79.

The Lancet. Infectious diseases·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Mar 12, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

11.1K

Does antimalarial mass drug administration increase or decrease the risk of resistance?

Nicholas J White1

  • 1Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

The Lancet. Infectious Diseases
|November 15, 2016
PubMed
Summary
This summary is machine-generated.

Mass drug administration (MDA) for malaria can reduce drug resistance by targeting symptomatic infections. Effective treatment lowers parasite numbers and transmission, mitigating resistance emergence in populations.

More Related Videos

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
10:22

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum

Published on: December 4, 2015

9.4K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

3.8K

Related Experiment Videos

Last Updated: Mar 12, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

11.1K
Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
10:22

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum

Published on: December 4, 2015

9.4K
Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

3.8K

Area of Science:

  • Malariology
  • Infectious Disease Epidemiology
  • Drug Resistance Studies

Background:

  • Antimalarial drug resistance is a persistent challenge, leading to treatment failures.
  • Mass drug administration (MDA) is often perceived as a primary driver of antimalarial drug resistance.
  • Understanding the dynamics of resistance emergence is crucial for effective malaria control.

Purpose of the Study:

  • To analyze the conditions under which antimalarial MDA influences the risk of drug resistance.
  • To differentiate the impact of parasite burden versus population exposure on resistance.
  • To inform strategies for mitigating antimalarial drug resistance.

Main Methods:

  • Conceptual analysis of parasite survival and spread dynamics.
  • Evaluation of asymptomatic versus symptomatic malaria infections.
  • Review of factors influencing resistance emergence in malaria-endemic regions.

Main Results:

  • Resistance risk is determined by the total number of parasites and their survival/spread probability, not solely by the number of people treated.
  • Symptomatic malaria cases with high parasite loads are the primary source for resistance emergence.
  • Asymptomatic infections, while common, harbor lower parasite burdens and are less likely to drive resistance.

Conclusions:

  • Antimalarial MDA can decrease resistance risk if it effectively reduces symptomatic cases and overall transmission.
  • Targeted mass treatment strategies focusing on high-parasite-burden infections are key.
  • Reducing transmission through effective treatment is a viable approach to combat antimalarial drug resistance.